Strategic Merger Peachtree BioResearch Solutions has merged into P95 Julius Clinical, creating a larger global CRO with integrated CNS, cardio-metabolic, and infectious disease capabilities. This expansion suggests opportunities to cross-sell CNS and cardiometabolic trial services to a broader, multinational client base.

Global Reach The combined entity emphasizes a global footprint with five continents and over 500 experts, enabling near-term discussions with multinational sponsors seeking diverse site networks and real-world evidence programs.

Therapeutic Focus Strong expertise across neuroscience, infectious diseases and vaccines, cardiovascular, renal, and metabolic diseases positions the company to pursue trial programs in high-growth areas, enabling targeted outreach to biotech and pharma sponsors prioritizing CNS and cardiometabolic assets.

Financial Position With revenue in the mid-range of tens of millions and recent leadership appointments, there is room to propose expanded scope trials, bigger phase studies, and integrated data analytics partnerships to lift trial value for sponsors.

Digital & Tools Current tech stack—including Sage Intacct, Power BI, SAS, GitHub, and SharePoint—facilitates data-driven offerings and streamlined collaboration. Propose analytics, reporting, and real-world evidence capabilities as value-adds to prospective clients.